415 related articles for article (PubMed ID: 25931452)
1. PET Imaging in Head and Neck Cancer Patients to Monitor Treatment Response: A Future Role for EGFR-Targeted Imaging.
van Dijk LK; Boerman OC; Kaanders JH; Bussink J
Clin Cancer Res; 2015 Aug; 21(16):3602-9. PubMed ID: 25931452
[TBL] [Abstract][Full Text] [Related]
2. Molecular targeted therapies in the management of head and neck squamous cell carcinoma: recent developments and perspectives.
Bozec A; Peyrade F; Milano G
Anticancer Agents Med Chem; 2013 Mar; 13(3):389-402. PubMed ID: 23092267
[TBL] [Abstract][Full Text] [Related]
3. PET of EGFR with (64) Cu-cetuximab-F(ab')2 in mice with head and neck squamous cell carcinoma xenografts.
van Dijk LK; Yim CB; Franssen GM; Kaanders JH; Rajander J; Solin O; Grönroos TJ; Boerman OC; Bussink J
Contrast Media Mol Imaging; 2016; 11(1):65-70. PubMed ID: 26242487
[TBL] [Abstract][Full Text] [Related]
4. Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer.
Keysar SB; Le PN; Anderson RT; Morton JJ; Bowles DW; Paylor JJ; Vogler BW; Thorburn J; Fernandez P; Glogowska MJ; Takimoto SM; Sehrt DB; Gan GN; Eagles-Soukup JR; Serracino H; Hirsch FR; Lucia MS; Thorburn A; Song JI; Wang XJ; Jimeno A
Cancer Res; 2013 Jun; 73(11):3381-92. PubMed ID: 23576557
[TBL] [Abstract][Full Text] [Related]
5. Lymphotoxin-β Interacts with Methylated EGFR to Mediate Acquired Resistance to Cetuximab in Head and Neck Cancer.
Hsu DS; Hwang WL; Yuh CH; Chu CH; Ho YH; Chen PB; Lin HS; Lin HK; Wu SP; Lin CY; Hsu WH; Lan HY; Wang HJ; Tai SK; Hung MC; Yang MH
Clin Cancer Res; 2017 Aug; 23(15):4388-4401. PubMed ID: 28196873
[No Abstract] [Full Text] [Related]
6. EGFR-targeted mAb therapy modulates autophagy in head and neck squamous cell carcinoma through NLRX1-TUFM protein complex.
Lei Y; Kansy BA; Li J; Cong L; Liu Y; Trivedi S; Wen H; Ting JP; Ouyang H; Ferris RL
Oncogene; 2016 Sep; 35(36):4698-707. PubMed ID: 26876213
[TBL] [Abstract][Full Text] [Related]
7. Is biomarker research advancing in the era of personalized medicine for head and neck cancer?
Yokota T
Int J Clin Oncol; 2014 Apr; 19(2):211-9. PubMed ID: 24442754
[TBL] [Abstract][Full Text] [Related]
8. Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC.
Swick AD; Prabakaran PJ; Miller MC; Javaid AM; Fisher MM; Sampene E; Ong IM; Hu R; Iida M; Nickel KP; Bruce JY; Wheeler DL; Kimple RJ
Mol Cancer Ther; 2017 Jul; 16(7):1257-1268. PubMed ID: 28446642
[TBL] [Abstract][Full Text] [Related]
9. ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis.
Lu H; Li X; Lu Y; Qiu S; Fan Z
Cancer Lett; 2016 Oct; 381(1):23-30. PubMed ID: 27450723
[TBL] [Abstract][Full Text] [Related]
10. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
[TBL] [Abstract][Full Text] [Related]
11. Challenges in EGFRvIII detection in head and neck squamous cell carcinoma.
Wheeler SE; Egloff AM; Wang L; James CD; Hammerman PS; Grandis JR
PLoS One; 2015; 10(2):e0117781. PubMed ID: 25658924
[TBL] [Abstract][Full Text] [Related]
12. Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: focus on potential molecular mechanisms of drug resistance.
Boeckx C; Baay M; Wouters A; Specenier P; Vermorken JB; Peeters M; Lardon F
Oncologist; 2013; 18(7):850-64. PubMed ID: 23821327
[TBL] [Abstract][Full Text] [Related]
13. Cetuximab Resistance in Head and Neck Cancer Is Mediated by EGFR-K
Braig F; Kriegs M; Voigtlaender M; Habel B; Grob T; Biskup K; Blanchard V; Sack M; Thalhammer A; Ben Batalla I; Braren I; Laban S; Danielczyk A; Goletz S; Jakubowicz E; Märkl B; Trepel M; Knecht R; Riecken K; Fehse B; Loges S; Bokemeyer C; Binder M
Cancer Res; 2017 Mar; 77(5):1188-1199. PubMed ID: 28031227
[TBL] [Abstract][Full Text] [Related]
14. MyD88-Dependent Signaling Decreases the Antitumor Efficacy of Epidermal Growth Factor Receptor Inhibition in Head and Neck Cancer Cells.
Koch AT; Love-Homan L; Espinosa-Cotton M; Stanam A; Simons AL
Cancer Res; 2015 Apr; 75(8):1657-67. PubMed ID: 25712126
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma.
Leblanc O; Vacher S; Lecerf C; Jeannot E; Klijanienko J; Berger F; Hoffmann C; Calugaru V; Badois N; Chilles A; Lesnik M; Krhili S; Bieche I; Le Tourneau C; Kamal M
Cancer Biol Med; 2020 Feb; 17(1):208-217. PubMed ID: 32296588
[No Abstract] [Full Text] [Related]
16. CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab.
Niehr F; Weichert W; Stenzinger A; Budach V; Tinhofer I
J Transl Med; 2015 Apr; 13():106. PubMed ID: 25890004
[TBL] [Abstract][Full Text] [Related]
17. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T
Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
Uribe P; Gonzalez S
Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor imaging in human head and neck cancer xenografts.
van Dijk LK; Boerman OC; Kaanders JH; Bussink J
Acta Oncol; 2015; 54(9):1263-7. PubMed ID: 26248024
[TBL] [Abstract][Full Text] [Related]
20. Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC).
Cohen RB
Cancer Treat Rev; 2014 May; 40(4):567-77. PubMed ID: 24216225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
